Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals · 60 locations · Updated 2026-11-18
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Hoffmann-La Roche · 105 locations · Updated 2026-11-18
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
University of Leeds · 5 locations · Updated 2026-11-16
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Kite, A Gilead Company · Locations not reported · Updated 2026-11-16
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
PrECOG, LLC. · 3 locations · Updated 2026-11-12
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Janssen Research & Development, LLC · Locations not reported · Updated 2026-11-04
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Janssen Research & Development, LLC · 103 locations · Updated 2026-11-03
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Janssen Research & Development, LLC · 270 locations · Updated 2026-11-03
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd · 1 locations · Updated 2026-11-02
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 141 locations · Updated 2026-10-29
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Pfizer · 180 locations · Updated 2026-10-27
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Alliance for Clinical Trials in Oncology · Locations not reported · Updated 2026-10-22
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
AstraZeneca · 114 locations · Updated 2026-10-21
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Kite, A Gilead Company · Locations not reported · Updated 2026-10-21
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie · 49 locations · Updated 2026-10-19
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Dana-Farber Cancer Institute · 3 locations · Updated 2026-10-09
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Intergroupe Francophone du Myelome · 69 locations · Updated 2026-09-30
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AstraZeneca · 143 locations · Updated 2026-09-29
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
AstraZeneca · 124 locations · Updated 2026-08-14
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Biocad · 16 locations · Updated 2026-08-03
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Polish Myeloma Consortium · Locations not reported · Updated 2026-07-31
GMMG-HD11/DSMM XXI/64007957MMY3010
University of Heidelberg Medical Center · Locations not reported · Updated 2026-06-26
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
PETHEMA Foundation · 68 locations · Updated 2026-06-25
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
GlaxoSmithKline · 181 locations · Updated 2026-04-22
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V. · 59 locations · Updated 2026-03-25
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd. · 1 locations · Updated 2026-01-29
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital · 13 locations · Updated 2025-03-20
KPD Consolidation After ASCT in NDMM Patients
Peking University People's Hospital · 3 locations · Updated 2025-03-17
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
University Hopsital Schleswig Holstein Campus Lübeck · 6 locations · Updated 2024-12-11
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 69 locations · Updated 2026-11-18
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 138 locations · Updated 2026-11-16
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 227 locations · Updated 2026-11-09
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Noffar Bar · 3 locations · Updated 2026-11-06
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-11-04
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
National Cancer Institute (NCI) · 81 locations · Updated 2026-11-04
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI) · 32 locations · Updated 2026-11-04
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Janssen Research & Development, LLC · 20 locations · Updated 2026-11-03
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-11-02
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-11-02
Showing 1–40 of 120. Older studies
More hematologic trials (152) that list MRD only as a secondary endpoint
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
AbbVie · 7 locations · Updated 2026-11-17
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
Qilu Pharmaceutical Co., Ltd. · Locations not reported · Updated 2026-11-12
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer · 268 locations · Updated 2026-11-12
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals · 159 locations · Updated 2026-11-06
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals · 33 locations · Updated 2026-11-04
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC · 157 locations · Updated 2026-11-03
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene · 266 locations · Updated 2026-10-30
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC · 173 locations · Updated 2026-09-25
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd. · 1 locations · Updated 2026-09-17
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Pfizer · 237 locations · Updated 2026-08-24
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
CellCentric Ltd. · 1 locations · Updated 2026-08-19
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Hangzhou Sumgen Biotech Co., Ltd. · 12 locations · Updated 2026-07-10
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network · 397 locations · Updated 2026-06-10
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd. · 1 locations · Updated 2026-05-22
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 49 locations · Updated 2026-05-08
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · 1 locations · Updated 2026-03-25
A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
Shanghai Henlius Biotech · 1 locations · Updated 2025-03-26
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
University of Leeds · 91 locations · Updated 2018-06-19
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI) · 152 locations · Updated 2026-11-18
18F-Fluciclovine PET/CT in Multiple Myeloma
National Cancer Institute (NCI) · 1 locations · Updated 2026-11-12
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd · 21 locations · Updated 2026-11-12
SKCD in Early Relapsed/Refractory Multiple Myeloma
Beijing Chao Yang Hospital · 1 locations · Updated 2026-11-12
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd · 1 locations · Updated 2026-11-06
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Hoffmann-La Roche · 16 locations · Updated 2026-11-05
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals · 9 locations · Updated 2026-11-05
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Hoffmann-La Roche · 5 locations · Updated 2026-11-05
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Polina Stepensky · 1 locations · Updated 2026-11-04
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC · 78 locations · Updated 2026-11-03
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca · 46 locations · Updated 2026-10-30
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie · 51 locations · Updated 2026-10-27
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Regeneron Pharmaceuticals · 40 locations · Updated 2026-10-26
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences · 2 locations · Updated 2026-10-26
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
University College, London · 14 locations · Updated 2026-10-20
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
AbbVie · 36 locations · Updated 2026-10-19
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
AstraZeneca · 36 locations · Updated 2026-10-08
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 52 locations · Updated 2026-10-06
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Fortvita Biologics (USA)Inc. · 6 locations · Updated 2026-09-25
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc. · 10 locations · Updated 2026-09-23
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
University of Chicago · 2 locations · Updated 2026-09-23
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health · 2 locations · Updated 2026-09-21
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-09-18
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
UCARsgen Biotech Limited · 2 locations · Updated 2026-09-17
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-09-17
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital · 3 locations · Updated 2026-09-16
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-09-16
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Larysa Sanchez · 1 locations · Updated 2026-09-14
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University · 1 locations · Updated 2026-09-03
Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
Dana-Farber Cancer Institute · 2 locations · Updated 2026-09-03
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene · 22 locations · Updated 2026-09-02
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas · 1 locations · Updated 2026-09-02
Elranatamab in R/R Multiple Myeloma
Massachusetts General Hospital · 3 locations · Updated 2026-08-31
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Natalie Callander · 1 locations · Updated 2026-08-31
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline · 59 locations · Updated 2026-08-25
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
GlaxoSmithKline · 44 locations · Updated 2026-08-19
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals · 9 locations · Updated 2026-08-05
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Shanghai Zhongshan Hospital · 1 locations · Updated 2026-08-03
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University · 1 locations · Updated 2026-07-17
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Irene Ghobrial, MD · 3 locations · Updated 2026-07-16
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic · 1 locations · Updated 2026-07-14
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd. · 4 locations · Updated 2026-07-10
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Regeneron Pharmaceuticals · 39 locations · Updated 2026-07-08
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-07
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline · Locations not reported · Updated 2026-06-24
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center · 5 locations · Updated 2026-06-02
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf · 5 locations · Updated 2026-05-18
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V. · 29 locations · Updated 2026-04-15
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech · 1 locations · Updated 2026-04-13
Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. · 3 locations · Updated 2026-04-03
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-03-04
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd. · 10 locations · Updated 2026-02-25
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
University of Miami · 3 locations · Updated 2026-02-23
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Hebei Senlang Biotechnology Inc., Ltd. · Locations not reported · Updated 2026-02-19
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2026-01-16
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD · 1 locations · Updated 2025-12-31
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
YOUNGIL KOH · 7 locations · Updated 2025-12-03
Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia
Fundacion Clinic per a la Recerca Biomédica · 7 locations · Updated 2025-04-25
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2025-04-16
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Biocad · 20 locations · Updated 2025-02-04
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Insel Gruppe AG, University Hospital Bern · 1 locations · Updated 2024-07-08
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
Beijing Mabworks Biotech Co., Ltd. · 1 locations · Updated 2024-03-15
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Affiliated Hospital of Nantong University · 1 locations · Updated 2024-02-07
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shanghai AbelZeta Ltd. · 1 locations · Updated 2023-03-24
Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
Hrain Biotechnology Co., Ltd. · 2 locations · Updated 2022-12-09
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2021-09-23
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc. · 29 locations · Updated 2026-11-18
BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
Liping Dou · 1 locations · Updated 2026-11-10
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-11-09
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals · 42 locations · Updated 2026-11-05
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Omar Nadeem, MD · 3 locations · Updated 2026-11-02
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI) · 17 locations · Updated 2026-10-27
Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
Hadassah Medical Organization · 1 locations · Updated 2026-10-20
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc · 11 locations · Updated 2026-10-20
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Hadassah Medical Organization · 1 locations · Updated 2026-10-16
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Washington University School of Medicine · 1 locations · Updated 2026-10-15
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca · 13 locations · Updated 2026-09-25
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Universitaire Ziekenhuizen KU Leuven · 17 locations · Updated 2026-09-25
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Chinese PLA General Hospital · 3 locations · Updated 2026-09-15
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
Fondazione EMN Italy Onlus · 10 locations · Updated 2026-09-09
Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Shambavi Richard · 1 locations · Updated 2026-07-27
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-07-24
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Montefiore Medical Center · Locations not reported · Updated 2026-07-22
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-07-21
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Chongqing Precision Biotech Co., Ltd · 1 locations · Updated 2026-07-20
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine · 1 locations · Updated 2026-07-09
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Shanghai Zhongshan Hospital · 13 locations · Updated 2026-06-23
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-06-16
PET-Enabled Dual-Energy CT in Multiple Myeloma
University of California, Davis · 1 locations · Updated 2026-06-15
Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)
Zhongshan Hospital (Xiamen), Fudan University · Locations not reported · Updated 2026-06-03
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Peter MacCallum Cancer Centre, Australia · 1 locations · Updated 2026-05-27
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie · 27 locations · Updated 2026-05-12
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
David Avigan · 1 locations · Updated 2026-05-08
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
David Avigan · 2 locations · Updated 2026-05-07
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
University Hospital, Toulouse · 1 locations · Updated 2026-04-29
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 locations · Updated 2026-04-17
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · 5 locations · Updated 2026-04-14
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
FengYan Jin · 1 locations · Updated 2026-04-03
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Sanofi · 19 locations · Updated 2026-03-25
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Alfred Chung, MD · 1 locations · Updated 2026-03-13
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University · 1 locations · Updated 2026-03-12
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine · 1 locations · Updated 2026-03-11
SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-02-10
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd · 12 locations · Updated 2026-02-05
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine · 1 locations · Updated 2026-01-22
IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-01-20
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd. · 1 locations · Updated 2026-01-13
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
Peking University People's Hospital · 1 locations · Updated 2026-01-06
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Nanjing Legend Biotech Co. · 4 locations · Updated 2025-12-29
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Peking University People's Hospital · 1 locations · Updated 2025-12-22
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 14 locations · Updated 2025-12-11
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-25
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2025-10-01
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
Tianjin Medical University Cancer Institute and Hospital · 2 locations · Updated 2025-08-11
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-01
A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University · Locations not reported · Updated 2025-06-12
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Chunrui Li · 1 locations · Updated 2025-06-11
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
The First Affiliated Hospital of Soochow University · Locations not reported · Updated 2025-06-11
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University · 1 locations · Updated 2025-05-31
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Nanjing IASO Biotechnology Co., Ltd. · 1 locations · Updated 2025-05-20
VitD3 Supplementation in Patients With Multiple Myeloma
Amany Keruakous, MD, MS. · 1 locations · Updated 2025-04-08
LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma
First Affiliated Hospital of Wenzhou Medical University · Locations not reported · Updated 2025-03-21
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 locations · Updated 2025-03-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd · 1 locations · Updated 2024-12-13
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital · 1 locations · Updated 2024-12-12
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 2 locations · Updated 2024-12-06
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2024-11-12
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Zhejiang University · 3 locations · Updated 2024-11-08
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Peking University People's Hospital · Locations not reported · Updated 2024-10-23
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd. · 1 locations · Updated 2024-08-02
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University · 4 locations · Updated 2024-06-28
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure · 1 locations · Updated 2024-05-03
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Hrain Biotechnology Co., Ltd. · 1 locations · Updated 2023-09-21
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.